ABBOTINDIA Abbott India Ltd Product Launches Announcement 2024 - New Therapy Launch Abbott India Limited has signed a non-exclusive patent license agreement with Takeda Pharmaceuticals to market and distribute the novel gastrointestinal therapy, Vonoprazan (branded as Vonefi), in India, which offers a once daily dose for severe acid-related disorders, improving patient compliance..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Abbott India Ltd